<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798261</url>
  </required_header>
  <id_info>
    <org_study_id>18135</org_study_id>
    <nct_id>NCT04798261</nct_id>
  </id_info>
  <brief_title>Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System</brief_title>
  <official_title>STRIKE-PE: A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate real world long-term functional outcomes, safety&#xD;
      and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Composite of major adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>A composite of device-related death, major bleeding, device-related clinical deterioration, device-related pulmonary vascular injury and device-related cardiac injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance: Change in RV/LV Ratio</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <description>Change in RV/LV Ratio (matched imaging pairs CTA or echocardiogram, as available)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed via PEmb-QoL</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Self-assessment of PE related complaints and daily living limitations (including work and social)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed via EQ-5D-5L</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Self-assessment of activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed NYHA</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Physician assessment of heart failure symptoms and activity level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome assessed via 6MWT</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Walking distance over a 6 minute period to assess functional capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived dyspnea assessed via Borg Scale</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Category rating scale to measure perceived dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device related SAE(s)</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any-cause mortality</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic PE recurrence</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Patients with acute pulmonary embolism</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indigo Aspiration System</intervention_name>
    <description>Indigo Aspiration System</description>
    <arm_group_label>Patients with acute pulmonary embolism</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute pulmonary embolism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less&#xD;
&#xD;
          2. RV/LV ratio ≥ 0.9 assessed by diagnostic computed tomographic angiography (CTA) or&#xD;
             echocardiogram&#xD;
&#xD;
          3. Frontline endovascular treatment with the Indigo Aspiration System per IFU&#xD;
&#xD;
          4. Patient is ≥ 18 years of age&#xD;
&#xD;
          5. Informed consent obtained per Institutional Review Board/Ethics Committee requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to systemic or therapeutic doses of anticoagulants (e.g. heparin)&#xD;
&#xD;
          2. Stage III/IV cancer or cancer which requires active chemotherapy during the course of&#xD;
             the study&#xD;
&#xD;
          3. Known serious, uncontrolled sensitivity to radiographic agents&#xD;
&#xD;
          4. Life expectancy &lt; 180 days&#xD;
&#xD;
          5. Patients on ECMO&#xD;
&#xD;
          6. Pregnant patients&#xD;
&#xD;
          7. Current participation in another investigational drug or device study that may&#xD;
             confound the results of this study. Studies requiring extended follow-up for products&#xD;
             that were investigational but have since become commercially available are not&#xD;
             considered investigational studies&#xD;
&#xD;
          8. Other medical, social, or psychological conditions that, in the opinion of the&#xD;
             Investigator, precludes the patient from appropriate consent, could limit the&#xD;
             patient's ability to participate in the study, including compliance with follow-up&#xD;
             requirements, or that could impact the scientific integrity of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meghan Beatty</last_name>
    <phone>757-759-2898</phone>
    <email>mbeatty@penumbrainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Archard</last_name>
    <phone>802-377-9715</phone>
    <email>earchard@penumbrainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radiology and Imaging Specialists</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fakhir Elmasri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonious Attallah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjum Sethi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Dexter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

